Accuray (NASDAQ:ARAY – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday, Wall Street Zen reports.
Separately, Weiss Ratings lowered Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 1st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.
Check Out Our Latest Stock Report on Accuray
Accuray Stock Down 1.9%
Accuray (NASDAQ:ARAY – Get Free Report) last released its earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.40. Accuray had a negative return on equity of 35.36% and a negative net margin of 4.41%. The firm had revenue of $100.92 million for the quarter, compared to analyst estimates of $105.30 million.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE bought a new stake in Accuray in the 2nd quarter valued at $28,000. Hsbc Holdings PLC acquired a new stake in Accuray during the second quarter valued at approximately $29,000. Williams & Novak LLC grew its stake in shares of Accuray by 30.9% in the 2nd quarter. Williams & Novak LLC now owns 238,230 shares of the medical equipment provider’s stock valued at $61,000 after purchasing an additional 56,200 shares during the period. Williams & Novak Wealth Management LLC grew its stake in shares of Accuray by 27.3% in the 3rd quarter. Williams & Novak Wealth Management LLC now owns 303,330 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 65,100 shares during the period. Finally, Ieq Capital LLC bought a new position in shares of Accuray during the 2nd quarter worth approximately $86,000. 64.08% of the stock is owned by institutional investors.
Accuray Company Profile
Accuray Incorporated develops, manufactures, and sells radiation therapy systems and related software for treating cancer and other conditions. Its technologies are used by hospitals and cancer treatment centers to plan and deliver radiation treatments. The company’s products include the CyberKnife platform, a robotic system designed to deliver stereotactic radiosurgery and radiation therapy, and the Radixact platform, which uses helical tomotherapy to deliver image-guided radiation treatments. Accuray also provides treatment-planning software, service, and support for its systems.
Further Reading
- Five stocks we like better than Accuray
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.
